Psoriatic Arthritis
Conference Coverage
VIDEO: Predicting anti-TNF failure in psoriatic arthritis
Conference Coverage
WCD: Ustekinumab succeeds as switch agent in psoriasis
Of 65 psoriasis patients switched to ustekinumab after failing initial anti-TNF therapy, 47 (72%) achieved PASI 75 within 12 weeks.
Conference Coverage
WCD: Tofacitinib’s benefits for psoriasis persist for 2 years
Key clinical point: Oral tofacitinib showed sustained efficacy for moderate to severe plaque psoriasis at 24 months in a large ongoing phase III...
Conference Coverage
Anti-TNFs help psoriatic arthritis patients get back to work
Key clinical point: Work disability is a reversible outcome in psoriatic arthritis and improves significantly more with use of anti-TNF drugs than...
News
Fathers factor in psoriatic disease
News
Psoriasis, PsA increase temporomandibular disorder risk
News
Chromosome deletion linked to PsA risk
Conference Coverage
BSR: Multiple benefits seen with intensive psoriatic arthritis therapy
News
New psoriatic arthritis risk locus unrelated to psoriasis found
News
New teaching tool could help doctors screen for PsA
News
Systemic psoriasis treatment may resolve subclinical enthesitis
Key clinical point: Systemic treatment of ultrasonographic enthesitis in psoriasis patients significantly mitigates morphologic abnormalities...